Deferoxamine mesylate for injection is an iron-chelating agent indicated.
From the U.S. FDA-approved label for Deferoxamine. Full label: DailyMed.
Deferoxamine mesylate for injection is an iron-chelating agent indicated.
From the U.S. FDA-approved label for Deferoxamine. Full label: DailyMed.
SECTION The dosage (based on body weight in mg/kg/day), rates of administration, and mode of administration for both adults and pediatric patients are individually determined and adapted during the course of therapy based on the severity of the patient’s iron overload. The minimum daily dose of deferoxamine mesylate for injection is 20 mg/kg/day for both adults and pediatric patients. The maximum daily dose is 40 mg/kg/day for pediatric patients and 60 mg/kg/day for adults.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Deferoxamine mesylate for injection is contraindicated in patients with: A history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients. Reactions have included anaphylaxis. Severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney. Known hypersensitivity to the active substance. Patients with severe renal disease or anuria.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Hypersensitivity Reactions: More common with rapid intravenous infusion. Administer intramuscularly or by slow subcutaneous or intravenous infusion. Auditory and Ocular Toxicity: Have been reported when administered over prolonged periods of time, at high doses, or in patients with low ferritin levels. Renal Toxicity: Cases of acute renal failure, renal tubular disorders and increase in serum creatinine have occurred. Monitor patients for changes in renal function. Respiratory Toxicity: Acute respiratory distress syndrome has occurred. Risk increased with high intravenous doses.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Auditory and Ocular Toxicity Renal Toxicity Respiratory Toxicity Growth Suppression Serious Infections Cardiac Dysfunction with Concomitant Use of Vitamin C Risks of Deferoxamine mesylate Treatment in Patients with Aluminum Overload Effects on Ability to Drive and Use Machines Most common adverse…
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
Store at 20° to 25°C (68° to 77°F).
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
